Paul Hastings is advising a Korean private equity-backed consortium on its take-private deal for Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials.
Jones Day and Cincinnati, Ohio-based law firm Keating Muething & Klekamp PLL are advising Cincinnati-based Meridian on the all-cash transaction valued at around $1.53 billion and expected to close in 2022’s fourth quarter.
The agreement calls for the consortium, made up of Seoul-based private equity firm SJL Partners LLC, and in vitro diagnostic test maker SD Biosensor, Inc., to pay $34 per share for Meridian.
The deal helps SD Biosensor enter the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.